title: New class of kinase inhibitors poised to join the anticancer arsenal.
authors.forename: Alisa
authors.initials: A
authors.lastname: Opar
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D015195:Drug Design; D004345:Drug Industry; D006801:Humans; D020935:MAP Kinase Signaling System / Q000187:drug effects; D020929:Mitogen-Activated Protein Kinase Kinases / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D020929:Mitogen-Activated Protein Kinase Kinases